Day 1 Antibody Congress

Dr Javad Aman

PLENARY KEYNOTE: Attacking Ebola with a Trojan Horse: A dual bispecific antibody cocktail targeting Ebola’s Niemann-Pick C1 (NPC1) binding protein

  • Overcoming monoclonal antibody approach for Ebola, which has limitations in targeting multiple viruses in same family
  • Capitalizing on filovirus biology: how understanding the virus pathogenicity mechanism helps in engineering a smart bispecific
  • Overcoming the “invisibility cloak” – getting inside the lysosomes on the back of Ebola with a dual bi-specific, making it the architect of its own destruction
Niksa Kastrapeli

PLENARY KEYNOTE: Discovery, characterization and proof of concept study for an antibody inhibitor of Factor XIIa

  •     Preclinical data for development of DX-4012 as an inhibitor of Factor XIIa
  •     This shows potential as a novel antithrombotic therapy
  •     Future interest areas and implications for autoimmune disorders and thrombosis
Prof Sy-Jye Leu

Anti-CaENO1 antibodies and humanized antibodies as an effective diagnostic agent or therapeutic treatment against infections caused by Candida spp

  • Anti-CaENO1 antibodies and humanized antibodies are provided as an effective diagnostic agent or a therapeutic treatment against infections caused by Candida spp., preferably Candida albicans, Candida tropicalis, fluconazole resistance Candida spp., Strepcococcus, Staphylococcus.
  • Outline of work conducted in this field and potential implications for treatment of infectious disease using therapeutic antibodies.




Dr Julie Bailis

Cellular mechanism of action of bispecific T-cell engager (BiTE®) antibody constructs targeting Folate Receptor 1

  • Bispecific T-cell engaging (BiTE®) antibody constructs connect T cells to target-positive cells to induce cytotoxicity.
  • Clinical proof of concept was achieved in B cell malignancies with the anti-CD19 BiTE® Blincyto®, and several BiTE® antibody constructs are currently in development for solid tumor indications.
  • With the goal of developing a BiTE® for ovarian cancer, this paper focuses on targeting the Folate Receptor (FOLR1). FOLR1 mRNA and protein are highly expressed in >80% of ovarian tumor samples.
Dr Julie Bailis, Principal Scientist, Amgen

Target Selection and Validation

Qiang Chen

A novel approach to mAb-based therapeutics


Binding strategies for infectious diseases





Kevin Heyries

High throughput single cell screening from humans for the discovery and generation of antibodies against bacterial pathogens

  • Multi-parametric serological profiling of human donors provide insight into individual's reactivity against bacterial pathogens
  • AbCellera's high throughput single cell antibody discovery platform enables screening of immune tissues to provide unique and diverse potent lead monoclonal antibodies against Klebsiella pneumoniae
  • Data regarding rapid isolation of hundreds of antibodies will be presented and discussed. 
Kevin Heyries, Co Founder, AbCellera

Novel Antibody Platforms and Screening Technology

Dr David Meininger

The Trianni Mouse: best-in-class technology for human antibody discovery

  • The Trianni Mouse is the only human transgenic antibody discovery platform offering a complete heavy, kappa and lambda repertoire in a single organism.
  • Sequences of the variable domain exons are human while all genetic machinery including extensively optimized promoters and enhancers are of mouse origin. Titers and class switching are extremely robust making for highly efficient lead generation.
  • Additional strains in development include Plasma Ig, Autoimmune/All Epitope and a "true" Bispecific.
Dr Daniel Adriano Silva Manzano

De novo computational design of hyperstable miniprotein binders

  • New paradigm for protein design that allows accurate engineering and subsequent experimental characterization of computationally designed hyperstable de novo miniprotein binders.
  • Examples of successfully engineered high-affinity binders and demonstrate how by massively encoding controlled variations of our designs we are able to prove multiple hypotheses of protein folding and binding, such as the importance of loop topology, hydrophobic cores and the role of disulfide bonds.
  • Results reveals unprecedented agreement between state-of-the-art computational metrics and experiments.

Engineering and Characterization

Bo Yu

Switchable Membrane Reporter (SwiMR) technology for recombinant protein expression and protein engineering

  • Switchable Membrane Reporter (SwiMR) technology utilizes a unique switchable reporter system to facilitate FACS-based enrichment and isolation of high producing cells of the protein of interest.
  • This eliminates the requirement for gene amplification and reduces cell line screening time from 4-8 months to 2-3 months. 
  • The SwiMR technology has been used to generate production CHO cells for multiple antibodies.
  • The top clones typically produce 1-4 g/L of antibodies in fed batch culture in commercial media.
Dr Hans Erickson

Understanding the factors that drive stability of protein conjugates

  •     Antibodies with cysteine mutations for conjugation are widely used for the preparation of homogeneous ADCs with defined molar ratios between the payload to the antibody. 
  •     The factors that drive stability are not well understood. 
  •     How we have optimized our cysteine engineering (THIOMAB™) technology to build better ADCs at Genentech will be discussed.
Dr Hans Erickson, Director of Protein Chemistry, Genentech


Rajiv Mahadevan

A harmonized approach to biomarker data management

  • Innovative informatics
  • Improve efficiency, quality and delivery of specialty lab data
  • Support of pre-clinical research and clinical trials

Innovative therapeutic approach

Greg Babcock

Designing and engineering antibody therapeutics for difficult-to-target proteins

  • Viral and bacterial proteins are mutable leading to antibody escape
  • Human proteins such as GPCRs and ion channels are poorly accessible to antibodies and have dynamic structures that alter epitope conformation and availability
  • Identifying and targeting conserved, functionally relevant, accessible epitopes on numerous proteins remains challenging
  • The Visterra Heirotope platform harmonizes structural, computational and experimental approaches to engineer antibodies to effectively engage these difficult targets


last published: 18/May/17 16:05 GMT